Online Pharmacy US

PHILADELPHIA – The auditor who examines applications for common benefit fees in the diet drug multidistrict litigation reports that as of March 31, attorneys have spent more than 553,000 hours on common benefit work wi th a cumulative lodestar value of more than $156 million (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 12 03, Sheila Brown, et al. v. American Home Products Corp., No. (more…)

Findings from a multicenter, double-blind, placebo-controlled study are consistent with previously
reported data showing that tadalafil (Cialis) improves lower urinary tract symptoms associated with BPH. However,
the benefit cannot be explained by effects on pressure-flow urodynamics. (Source: Modern Medicine)

PHILADELPHIA – The judge supervising the American Home Products National Settlement has ordered the Settlement Trust to pay Matrix benefits to two former diet drug users, but affirmed the trust’s denial of benefits to a third (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.).
Full story on lexis.com (Source: (more…)

PHILADELPHIA – A diet drug attorney whose conflict of interest allegation regarding the distribution of common benefit fees was dismissed as premature but obtained a sympathetic concurring opinion in the Third Circuit U.S. Court of A ppeals has renewed his objection before the district court to the massive application for a final award of common benefit fees and costs (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability (more…)

PHILADELPHIA – The judge supervising the American Home Products National Diet Drug Settlement on July 10 denied a Wyeth motion and ordered the Settlement Trust to pay benefits to a claimant whose use of the drugs Wyeth contested (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.).
Full story on lexis. com (more…)

PHILADELPHIA – Calling it the “largest private-party settlement in the history of American litigation,” attorneys who administered the multidistrict litigation (MDL) over America n Home Products’ diet drugs and negotiated the settlement valued at more than $5 billion on July 16 applied for a $403 million final award of common benefit fees (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. (more…)

PHILADELPHIA – A prominent diet drug plaintiff firm has filed objections to a common benefit fee application by a former assoc iate, saying any such fee belongs to the firm (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux (more…)

PHILADELPHIA – The judge supervising the American Home Pr oducts (AHP) National Settlement has made a final distribution of approximately $414 million in legal fees to the law firms that prosecuted the 10-year litigation and administered the resulting national settlement (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, (more…)

Findings from a multicenter, double-blind, placebo-controlled study are consistent with previously
reported data showing that tadalafil (Cialis) improves lower urinary tract symptoms associated with BPH. However,
the benefit cannot be explained by effects on pressure-flow urodynamics. (Source: Modern Medicine)

PHILADELPHIA – A diet drug attorney whose conflict of interest allegation regarding the distribution of common benefit fees was dismissed as premature but obtained a sympathetic concurring opinion in the Third Circuit U.S. Court of Appeals has renewed his objection before the district court to the massive application for a final award of common benefit fees and costs (In Re: Di et Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability (more…)